+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacovigilance Market by Component, Type, Product Life Cycle, Delivery Mode, Process Flow, Application, End-user, Deployment Model - Global Forecast 2026-2032- Product Image
Pharmacovigilance Market by Component, Type, Product Life Cycle, Delivery Mode, Process Flow, Application, End-user, Deployment Model - Global Forecast 2026-2032- Product Image
Sale

Pharmacovigilance Market by Component, Type, Product Life Cycle, Delivery Mode, Process Flow, Application, End-user, Deployment Model - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5306611
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pharmacovigilance Market is projected to reach USD 13.71 Billion in 2026. It is expected to continue growing at a CAGR of 16.34%, reaching USD 34.17 Billion by 2032.

Pharmacovigilance has moved from a back-office compliance function to a strategic capability for protecting patients, preserving product value, and meeting global drug safety obligations. As regulators expand expectations for adverse event reporting, risk management plans, periodic benefit-risk evaluation reports, and post-marketing surveillance, life sciences organizations are prioritizing faster case intake, stronger signal detection, and auditable safety governance.

The pharmacovigilance landscape is shaped by rising medicine utilization, complex biologics and vaccines, expanding clinical trial activity, and larger volumes of real-world safety data from electronic health records, claims, patient support programs, call centers, literature, social media, and digital health channels. Organizations that can convert these data streams into validated individual case safety reports, risk signals, and compliant regulatory submissions are better positioned to maintain inspection readiness, strengthen benefit-risk management, and improve patient outcomes.

Transformative Shifts in the Pharmacovigilance Landscape

The pharmacovigilance landscape is being transformed by regulatory harmonization, digitized safety operations, and a shift toward proactive benefit-risk management. Standards such as ICH E2B(R3), MedDRA coding, EU Good Pharmacovigilance Practices, FDA post-market reporting expectations, and WHO safety monitoring principles are encouraging more structured, interoperable, and traceable safety data exchange across global safety systems.

At the same time, safety teams are absorbing higher reporting volumes from specialty drugs, biologics, vaccines, combination products, social listening programs, digital therapeutics, telehealth, and patient engagement platforms. This is pushing sponsors and service providers to redesign operating models around automation, quality-by-design, global case processing hubs, local affiliate oversight, medical safety review, and integrated signal management to support timely regulatory compliance and patient safety decisions.

Cumulative Impact of Artificial Intelligence on Drug Safety

Artificial intelligence is having a cumulative impact across pharmacovigilance by improving the speed, consistency, and traceability of routine workflows. Natural language processing, machine learning classification, entity extraction, duplicate detection, automated narrative drafting, intelligent MedDRA coding, and literature screening can reduce manual effort in case intake, triage, and quality control when implemented with validated rules and human oversight.

The strongest use cases are emerging where AI supports, rather than replaces, qualified safety professionals. Regulators continue to expect explainability, audit trails, documented validation, data privacy safeguards, and medical judgment for causality assessment, seriousness evaluation, expectedness review, and signal detection. As a result, AI adoption is most effective when embedded in governed safety systems that align with GxP quality standards, risk-based validation, cybersecurity controls, and transparent change management.

Key Regional Insights for Pharmacovigilance

Asia-Pacific is gaining importance as China, India, Japan, South Korea, Australia, and ASEAN markets expand clinical development, generic and biosimilar manufacturing, and national adverse event reporting systems. Regulatory authorities across the region are increasing expectations for local case reporting, risk management, and post-authorization safety monitoring, making regional pharmacovigilance coordination critical for sponsors operating across diverse languages, formats, and timelines. North America remains a mature center for pharmacovigilance innovation, supported by FDA FAERS, the Sentinel Initiative, REMS oversight, Health Canada reporting requirements, extensive clinical research activity, and established life sciences outsourcing capacity.

Latin America is strengthening post-marketing surveillance as Brazil, Mexico, and other markets modernize regulatory procedures and increase local safety reporting expectations. Europe continues to set a high bar through the European Medicines Agency, EudraVigilance, EU Good Pharmacovigilance Practices, formal risk management planning, and periodic safety reporting obligations. The Middle East is advancing national pharmacovigilance centers, electronic reporting, and local safety responsibilities as healthcare systems digitalize, while Africa is building medicine safety capacity through national regulatory authorities, WHO program participation, adverse event monitoring for vaccines and essential medicines, and stronger reliance-based regulatory collaboration as medicine access expands.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly aligned around regional reliance, local safety reporting, pharmacovigilance capacity building, and regulatory cooperation, making the bloc important for companies seeking scalable Asia-Pacific safety models. The GCC is advancing medicine safety oversight across Gulf states through regulatory coordination, hospital reporting systems, national health strategies, and digital health investments that generate more structured safety data for post-marketing surveillance.

The European Union remains the global benchmark for rigorous pharmacovigilance governance through centralized procedures, EudraVigilance, legally defined responsibilities for marketing authorization holders, qualified person requirements, and EU Good Pharmacovigilance Practices. BRICS countries represent strategically important demand because of large patient populations, domestic pharmaceutical manufacturing, expanding clinical research participation, and maturing surveillance systems. G7 markets continue to shape advanced standards for data integrity, inspection readiness, AI governance, real-world evidence, and benefit-risk transparency, while NATO countries add relevance through health security, medical countermeasure monitoring, supply resilience, and safety surveillance for critical medicines used in emergency preparedness.

Key Country Insights in Global Pharmacovigilance

The United States leads in large-scale post-market surveillance through FDA FAERS, Sentinel, REMS oversight, mandatory reporting obligations, and a mature ecosystem of pharmaceutical sponsors and safety service providers. Canada maintains strong pharmacovigilance requirements through Health Canada and its adverse reaction reporting framework, while Mexico and Brazil are important Latin American markets as COFEPRIS and ANVISA continue to strengthen medicine safety oversight, regulatory modernization, and local reporting practices.

In Europe, the United Kingdom, Germany, France, Italy, and Spain remain central to clinical development, regulatory science, medical literature monitoring, and EU-aligned safety operations, with the United Kingdom operating through the MHRA and Yellow Card Scheme and EU members contributing to EudraVigilance-based surveillance. Russia requires localized regulatory attention due to national reporting expectations and local regulatory procedures. China and India are critical because of their scale in clinical research, manufacturing, pharmacovigilance program development, and patient populations; Japan and South Korea combine advanced regulatory systems with high adoption of structured safety data standards and strong post-marketing obligations; and Australia offers a mature, transparent system under the Therapeutic Goods Administration that supports regional pharmacovigilance planning across Asia-Pacific.

Actionable Recommendations for Pharmacovigilance Leaders

Industry leaders should prioritize a risk-based pharmacovigilance operating model that connects global safety databases, local affiliate processes, medical review, quality management, signal detection, and regulatory intelligence. Investing in interoperable platforms that support ICH E2B(R3), standardized MedDRA coding, automated case routing, literature screening, duplicate detection, audit trails, and compliant submissions can reduce cycle times while improving data quality and inspection readiness.

Organizations should also establish AI governance before scaling automation. Practical actions include validating algorithms, documenting model performance, preserving human medical oversight, monitoring bias, integrating privacy controls, maintaining vendor oversight, and training safety teams to work with intelligent workflow tools. Vendor partnerships should be assessed on inspection history, pharmacovigilance domain expertise, data security, multilingual coverage, regulatory submission capability, business continuity, and measurable quality outcomes.

Research Methodology

This executive summary is based on secondary research from publicly available regulatory guidance, international safety standards, national pharmacovigilance frameworks, and established industry practices. Core reference points include FDA post-marketing safety systems, EMA and EU GVP requirements, WHO pharmacovigilance principles, ICH safety data standards, MedDRA terminology practices, and country-level regulatory authority guidance.

The analysis applies a qualitative market intelligence approach, evaluating regulatory maturity, adverse event reporting infrastructure, technology adoption, outsourcing trends, clinical development activity, safety database interoperability, inspection expectations, and regional policy direction. Insights were synthesized to support strategic decision-making for pharmaceutical manufacturers, biotechnology companies, contract research organizations, pharmacovigilance service providers, medical affairs teams, and digital safety platform vendors without applying market sizing, market share, or forecast assumptions.

Conclusion

Pharmacovigilance is entering a more data-intensive and intelligence-led era in which speed, accuracy, interoperability, and transparency define operational advantage. Organizations that build modern safety architectures will be better prepared to manage global reporting complexity, detect emerging risks earlier, support compliant benefit-risk decisions, and maintain trusted relationships with regulators, clinicians, and patients.

As AI, real-world evidence, structured data standards, and harmonized regulatory expectations continue to mature, pharmacovigilance will increasingly support enterprise-wide benefit-risk strategy rather than isolated compliance tasks. Leaders that combine technology with medical expertise, quality discipline, validated governance, and regional regulatory intelligence can create resilient safety systems for the next generation of medicines.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pharmacovigilance Market, by Component
7.1. Software
7.2. Services
8. Pharmacovigilance Market, by Type
8.1. Cohort Event Monitoring
8.2. EHR Mining
8.3. Intensified ADR Reporting
8.4. Spontaneous Reporting
8.5. Targeted Spontaneous Reporting
9. Pharmacovigilance Market, by Product Life Cycle
9.1. Phase I
9.2. Phase II
9.3. Phase III
9.4. Phase IV
9.5. Pre-clinical
10. Pharmacovigilance Market, by Delivery Mode
10.1. In-house
10.2. Outsourced
11. Pharmacovigilance Market, by Process Flow
11.1. Case Data Management
11.1.1. Case Data Analysis
11.1.2. Case Logging
11.1.3. Medical Reviewing & Reporting
11.2. Risk Management System
11.2.1. Risk Evaluation System
11.2.2. Risk Mitigation System
11.3. Signal Detection
11.3.1. Adverse Event Analysis
11.3.2. Adverse Event Logging
11.3.3. Adverse Event Review & Reporting
12. Pharmacovigilance Market, by Application
12.1. Cardiovascular
12.2. Infectious Diseases
12.3. Neurology
12.4. Oncology
12.5. Respiratory
13. Pharmacovigilance Market, by End-user
13.1. Biotechnology Companies
13.2. Medical Device Manufacturers
13.3. Pharmaceuticals
14. Pharmacovigilance Market, by Deployment Model
14.1. On-Premises
14.2. Cloud-Based
14.3. Hybrid
15. Asia-Pacific Pharmacovigilance Market
16. North America Pharmacovigilance Market
17. Latin America Pharmacovigilance Market
18. Europe Pharmacovigilance Market
19. Middle East Pharmacovigilance Market
20. Africa Pharmacovigilance Market
21. ASEAN Pharmacovigilance Market
22. GCC Pharmacovigilance Market
23. European Union Pharmacovigilance Market
24. BRICS Pharmacovigilance Market
25. G7 Pharmacovigilance Market
26. NATO Pharmacovigilance Market
27. United States Pharmacovigilance Market
28. Canada Pharmacovigilance Market
29. Mexico Pharmacovigilance Market
30. Brazil Pharmacovigilance Market
31. United Kingdom Pharmacovigilance Market
32. Germany Pharmacovigilance Market
33. France Pharmacovigilance Market
34. Russia Pharmacovigilance Market
35. Italy Pharmacovigilance Market
36. Spain Pharmacovigilance Market
37. China Pharmacovigilance Market
38. India Pharmacovigilance Market
39. Japan Pharmacovigilance Market
40. Australia Pharmacovigilance Market
41. South Korea Pharmacovigilance Market
42. Competitive Landscape
42.1. Market Concentration Analysis, 2025
42.1.1. Concentration Ratio (CR)
42.1.2. Herfindahl Hirschman Index (HHI)
42.2. Recent Developments & Impact Analysis, 2025
42.3. Product Portfolio Analysis, 2025
42.4. Benchmarking Analysis, 2025
43. Company Profiles
43.1. Accenture, PLC
43.2. Bristol-Myers Squibb Company
43.3. Capgemini SE
43.4. ClinChoice
43.5. F. Hoffmann-La Roche AG
43.6. GlaxoSmithKline PLC
43.7. HCL Technologies Limited
43.8. ICON PLC
43.9. Infosys Limited
43.10. International Business Machines Corporation
43.11. IQVIA Inc.
43.12. ITclinical
43.13. Linical Co., Ltd.
43.14. Novartis AG
43.15. Oracle Corporation
43.16. Parexel International
43.17. Pfizer Inc.
43.18. Quanticate International limited
43.19. Sanofi S.A.
43.20. Syneos Health
43.21. TAKE Solutions Limited
43.22. TATA Consultancy Services Limited
43.23. Wipro Limited
List of Figures
FIGURE 1. GLOBAL PHARMACOVIGILANCE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PHARMACOVIGILANCE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PHARMACOVIGILANCE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PHARMACOVIGILANCE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2025 VS 2032 (%)
FIGURE 29. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 41. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. GCC PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. GCC PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. BRICS PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. BRICS PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. G7 PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. G7 PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. NATO PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 53. NATO PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 54. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. CANADA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. MEXICO PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. BRAZIL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. GERMANY PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. FRANCE PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. ITALY PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. SPAIN PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. CHINA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. INDIA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. JAPAN PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 67. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 68. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL COHORT EVENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL COHORT EVENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL COHORT EVENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL EHR MINING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL EHR MINING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL EHR MINING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL INTENSIFIED ADR REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INTENSIFIED ADR REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL INTENSIFIED ADR REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SPONTANEOUS REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SPONTANEOUS REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SPONTANEOUS REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL TARGETED SPONTANEOUS REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL TARGETED SPONTANEOUS REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL TARGETED SPONTANEOUS REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PHASE IV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PHASE IV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PHASE IV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PRE-CLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PRE-CLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PRE-CLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IN-HOUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL IN-HOUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL IN-HOUSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL OUTSOURCED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL OUTSOURCED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL OUTSOURCED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CASE DATA MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CASE DATA MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CASE DATA MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CASE DATA ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CASE DATA ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CASE DATA ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CASE LOGGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CASE LOGGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CASE LOGGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MEDICAL REVIEWING & REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MEDICAL REVIEWING & REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MEDICAL REVIEWING & REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL RISK MANAGEMENT SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL RISK MANAGEMENT SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL RISK MANAGEMENT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RISK EVALUATION SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL RISK EVALUATION SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL RISK EVALUATION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL RISK MITIGATION SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL RISK MITIGATION SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL RISK MITIGATION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SIGNAL DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL SIGNAL DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL SIGNAL DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ADVERSE EVENT ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ADVERSE EVENT ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ADVERSE EVENT ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ADVERSE EVENT LOGGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ADVERSE EVENT LOGGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ADVERSE EVENT LOGGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ADVERSE EVENT REVIEW & REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ADVERSE EVENT REVIEW & REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ADVERSE EVENT REVIEW & REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL RESPIRATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL RESPIRATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL RESPIRATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL ON-PREMISES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL ON-PREMISES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL ON-PREMISES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CLOUD-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CLOUD-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL CLOUD-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL HYBRID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL HYBRID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL HYBRID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 160. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 161. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 162. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 163. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 164. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 165. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 166. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 167. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 168. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 169. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 170. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 171. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 184. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 185. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 186. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 187. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 188. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 189. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 190. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 191. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 192. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 193. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 194. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 195. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 196. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 197. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 198. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 199. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 200. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 201. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 202. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 203. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 204. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 205. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 206. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 207. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 208. GCC PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 209. GCC PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 210. GCC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 211. GCC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 212. GCC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 213. GCC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 214. GCC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 215. GCC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 216. GCC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 217. GCC PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 218. GCC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 219. GCC PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 232. BRICS PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 233. BRICS PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 234. BRICS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 235. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 236. BRICS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 237. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 238. BRICS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 239. BRICS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 240. BRICS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 241. BRICS PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 242. BRICS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 243. BRICS PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 244. G7 PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 245. G7 PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 246. G7 PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 247. G7 PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 248. G7 PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 249. G7 PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 250. G7 PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 251. G7 PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 252. G7 PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 253. G7 PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 254. G7 PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 255. G7 PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 256. NATO PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 257. NATO PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 258. NATO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 259. NATO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 260. NATO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 261. NATO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 262. NATO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 263. NATO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 264. NATO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 265. NATO PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 266. NATO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 267. NATO PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 270. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 271. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 272. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 273. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 274. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 275. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 276. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 277. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 278. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 279. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 280. CANADA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 281. CANADA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 282. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 283. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 284. CANADA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 285. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 286. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 287. CANADA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 288. CANADA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 289. CANADA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 290. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 291. CANADA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 292. MEXICO PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 293. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 294. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 295. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 296. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 297. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 298. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 299. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 300. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 301. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 302. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 303. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 304. BRAZIL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 305. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 306. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 307. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 308. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 309. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 310. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 311. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 312. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 313. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 314. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 315. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 316. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 317. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 318. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 319. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 320. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 321. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 322. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 323. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 326. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 327. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 328. GERMANY PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 329. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 330. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 331. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 332. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 333. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 334. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 335. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 336. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 337. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 338. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 339. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 340. FRANCE PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 341. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 342. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 343. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 344. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 345. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 346. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 347. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 348. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 349. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 350. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 351. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 352. RUSSIA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 353. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 354. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 355. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 356. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 357. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 358. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 359. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 360. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 361. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 362. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 363. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
TABLE 364. ITALY PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 365. ITALY PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 366. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 367. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 368. ITALY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 369. ITALY PHARMACOVIGILA

Companies Mentioned

The companies featured in this Pharmacovigilance market report include:
  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi S.A.
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited

Table Information

Report AttributeDetails
No. of Pages194
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.71 Billion
Forecasted Market Value ( USD ) by 2032 $ 34.17 Billion
Compound Annual Growth Rate16.3%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Pharmacovigilance & Drug Safety Software Market by Software Type, Organization Size, Pharmacovigilance Type, Deployment Mode, Clinical Trial Phase, End User, Application - Global Forecast 2026-2032 - Product Image

Pharmacovigilance & Drug Safety Software Market by Software Type, Organization Size, Pharmacovigilance Type, Deployment Mode, Clinical Trial Phase, End User, Application - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Pharmacovigilance - Global Strategic Business Report - Product Image

Pharmacovigilance - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Clinical Safety & Pharmacovigilance Services Market - Global Forecast 2025-2030 - Product Image

Clinical Safety & Pharmacovigilance Services Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Pharmacovigilance Market Size, Share, Trends and Forecast by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region, 2026-2034 - Product Image

Pharmacovigilance Market Size, Share, Trends and Forecast by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region, 2026-2034

  • Report
  • 145 Pages
  • Global
From
Pharmacovigilance and Drug Safety Software - Global Strategic Business Report - Product Image

Pharmacovigilance and Drug Safety Software - Global Strategic Business Report

  • Report
  • 187 Pages
  • Global
From

About the Pharmacovigilance Market

The Pharmacovigilance market is a subset of the Healthcare Services industry, focusing on the monitoring and assessment of the safety of pharmaceutical products. It involves the collection, analysis, and reporting of adverse events related to the use of drugs, as well as the identification of potential risks associated with their use. Pharmacovigilance activities are conducted by pharmaceutical companies, regulatory authorities, and healthcare professionals. Pharmacovigilance activities are essential for the safe and effective use of drugs, as they help to identify potential risks and ensure that the benefits of the drug outweigh the risks. Pharmacovigilance also helps to ensure that the drug is used appropriately and that any adverse events are reported and addressed. Some companies in the Pharmacovigilance market include Parexel, Quintiles, Covance, PRA Health Sciences, and ICON. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.